Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOC-110 in Refractory or Unexplained Chronic Cough
NCT06504446Phase 2Active, not recruiting
- Sponsor
- Nocion Therapeutics
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of taplucainium chloride in refractory chronic cough (RCC), sponsored by Nocion Therapeutics. Started Sep 2024; status: active, not recruiting.
02
Drugs
taplucainium chloride
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT06504446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504446.